Polydeoxyribonucleotide
PreclinicalPeptide
Polydeoxyribonucleotide is one of 15 small molecule programs targeting Lateral Epicondylitis. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Lateral Epicondylitis
#DrugCompanyPhaseTrials
1Aleve
Jazz PharmaceuticalsApproved
Kenalog
BBassett Healthcare
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Iev
SShanghai 6th People's Hospital
Phase 2
Botox
RRevance Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lateral Epicondylitis1 trial
Polydeoxyribonucleotide for Elbow Lateral Epicondylitis
Completed·—·N/A·NCT06753630·48 enrolled
Diabetic Ulcer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Polydeoxyribonucleotide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Messina